Dr. Jitendra Singh Urges Industry to Accelerate Commercialisation of Indian Innovation, Scale Up Capabilities for Strategic Sovereignty by 2047

1. At a Glance

• The Union Minister of State for Science & Technology asked industry to move scientific research into commercial ventures. He linked this to strategic sovereignty and to India's national objectives for 2047 [1].
• His main argument: India should move from adopting technologies built elsewhere to creating indigenous solutions with global relevance [1].
• He backed the argument with progress figures from flagship programmes: the National Quantum Mission (quantum-secure communication), the bioeconomy (BioE3) and the Research, Development and Innovation (RDI) initiative [1].
• UPSC value: this is a strong GS-III example for questions on indigenisation of technology, industry–academia linkage, frontier technologies and the bioeconomy.

2. Why in the News

• 10 Oct 2026: Dr. Jitendra Singh gave the address at the 121st Annual Session of the PHD Chamber of Commerce and Industry (PHDCCI) in New Delhi [1].
• He said India had reached 1,000 km of quantum-secure communication in 3 years, against an 8-year target of 2,000 km [1].
• He said India's bioeconomy is now about US$196 billion (the release headline says "exceeds US$195 billion"), with a target of US$300 billion by 2030 [1].

3. Background & Evolution

• 2014: India's bioeconomy stood at about US$10 billion [1][3].
• 19 Apr 2023: The Union Cabinet approved the National Quantum Mission (NQM) at ₹6003.65 crore for 2023-24 to 2030-31 [2].
• 24 Aug 2024: The Union Cabinet approved the BioE3 Policy [3].
• 2024: The bioeconomy reached US$165.7 billion, about 16 times its 2014 size [3].
• 27 Mar 2025: A PIB backgrounder put the bioeconomy at 4.25% of GDP, with a 17.9% CAGR over the previous four years [3].
• Oct 2026: The minister cited a bioeconomy of about US$196 billion and the 1,000 km quantum-communication milestone [1].
• Related earlier initiatives:
• National Biopharma Mission (Innovate in India, i3): led by DBT, implemented by BIRAC, budget US$250 million, co-funded by the World Bank [3].
• BIRAC: established in 2012; has set up 95 bio-incubation centres [3].

4. Core Static Facts

5. Multi-Dimensional Analysis

Scientific / Technological

• The minister asked for industry to be involved from the start of a research project, so that scientists understand market needs and have a clear path to commercial deployment [1].
• The chain he described runs from laboratory to prototype to market-ready product. Industry bodies such as PHDCCI would link researchers with businesses and investment [1].
• The NQM covers computing, communication, sensing and materials, giving a broad frontier-technology base [2].

Economic

• Bioeconomy growth from US$10 bn to about US$196 bn is presented as evidence that science can create new enterprises and economic value [1].
• The RDI initiative aims to increase private-sector R&D participation so discoveries reach commercial use faster [1].
• Ethanol blending ties biotechnology to energy-import substitution and rural incomes [3].

Geopolitical / Strategic

• The minister stressed the strategic and security significance of quantum communication [1].
• He called indigenous technology and reliable energy supply prerequisites for India's ambitions in AI, data infrastructure and advanced manufacturing [1].
• He framed domestic capability in strategic technologies as central to strategic sovereignty [1].

Governance / Administrative

• He called for a whole-of-ecosystem partnership of Government, industry, academia, research institutions and start-ups [1].
• He cited the space ecosystem's expansion after policy reforms as an example of how an enabling policy environment draws in private participation [1].
• He said India's "next leap" depends on faster execution and the ability to scale successful innovations [1].

Environmental

• BioE3 promotes regenerative biomanufacturing and a circular bioeconomy, in line with India's net-zero goals [3].

6. Recent Developments (last 12–18 months)

• 27 Mar 2025: PIB backgrounder on the bioeconomy: US$165.7 bn in 2024, 4.25% of GDP, BioE3 hubs [3].
• 10 Oct 2026: At PHDCCI, the minister reported the 1,000 km quantum-secure communication milestone, a bioeconomy of about US$196 bn, and a push for private participation under the RDI initiative [1].

7. Prelims Hooks

• NQM was approved by the Union Cabinet on 19 April 2023 [2].
• NQM outlay: ₹6003.65 crore, for 2023-24 to 2030-31 [2].
• NQM targets quantum computers with 50–1000 physical qubits within 8 years [2].
• NQM targets satellite-based secure quantum communication over 2000 km between ground stations within India [2].
• NQM deliverables include atomic clocks and high-sensitivity magnetometers [2].
• 1,000 km of quantum-secure communication was achieved in 3 years (reported Oct 2026) [1].
• BioE3 = Biotechnology for Economy, Environment and Employment; Cabinet approval 24 Aug 2024 [3].
• BioE3 provides for Biomanufacturing hubs, Bio-AI hubs and Biofoundry [3].
• Bioeconomy grew from US$10 bn (2014) to US$165.7 bn (2024); target US$300 bn by 2030 [3].
• Bioeconomy share of GDP: 4.25% [3].
• The National Biopharma Mission is implemented by BIRAC and co-funded by the World Bank (US$250 mn) [3].
• India ranks 3rd by volume and 14th by value in pharmaceutical production [3].
• The PHDCCI session addressed was the 121st Annual Session [1].

8. Why Indian Industry Still Leaves Research to the Government

• India spends very little on research, and most of it is public money
• GERD (Gross Expenditure on R&D, meaning all research spending in the country) is only 0.64% of GDP, according to the Economic Survey 2025-26 [6].
• The government pays for about 64% of it. The private sector pays for only about 36% [6].

• In China, South Korea and the US, the private sector pays for more than 70% [7].

• This is the real problem behind the minister's appeal

• Moving from adopting technology to creating it needs companies to spend their own money on research.
• In OECD countries, businesses paid for 73% of all R&D in 2024 [9].

• Israel spends 6.8% of its GDP on R&D and Korea 5.1%, about eight to ten times India's share [9][6].

• The pharma ranking shows the same gap in a single sector

• India is 3rd by volume but only 14th by value in pharmaceutical production [3].
• In plain words, India makes large quantities of low-priced medicines, mostly generics (copies of medicines whose patents have expired). It earns much less from new, patented products.
• So the minister is describing the gap correctly. A speech alone does not change why companies avoid risky research.

9. What the ₹1 Lakh Crore RDI Fund Can and Cannot Fix

• The RDI Scheme is the government's main tool to bring in private money
• The Cabinet approved a corpus (a fixed pool of money) of ₹1 lakh crore over six years [8].
• A Special Purpose Fund inside ANRF (Anusandhan National Research Foundation) passes the money to second-level fund managers. Projects then get long-term loans at low or nil interest [8].

• The ANRF Governing Board, chaired by the Prime Minister, sets its direction. DST is the nodal department [8].

• Most of the money comes as loans, not grants, and that limits who can use it

• A loan has to be repaid. So it suits a firm whose product is close to the market and will soon earn money.
• The scheme says it will fund projects at higher Technology Readiness Levels [8]. TRL is a 1–9 scale of how close a technology is to real use. A high TRL means it is nearly ready.

• Early, uncertain research, the stage where the minister wants industry to be present "from the start" [1], is exactly where a firm may never earn enough to repay.

• The two layers of funding add a step between the money and the laboratory

• Money goes from ANRF to fund managers, and only then to projects [8].

• How fast money actually reaches firms depends on how quickly those managers choose projects. The minister himself said the "next leap" depends on faster execution [1].

• What the scheme does well

• It targets the same sectors as the speech: quantum, biotechnology and biomanufacturing, AI, space and energy transition [8].
• It also sets up a Deep-Tech Fund of Funds (a fund that invests in other venture funds, which then back start-ups) [8]. This gives start-ups equity, which they do not have to repay the way they repay a loan.

10. How to Read the Minister's Progress Numbers

• The 1,000 km quantum figure covers only one of several targets
• NQM has two separate 2,000 km communication goals. One is satellite-based links between ground stations. The other is inter-city QKD (Quantum Key Distribution, which uses quantum physics to share secret keys that cannot be copied without detection) [2].
• The speech does not say which of the two the 1,000 km belongs to [1]. So "half the target in three years" may describe one strand, not the whole mission.

• The speech gives no progress report on the 50–1000 qubit computing target [2][1]. Computing is also the hardest part to turn into a product.

• The bioeconomy target is less ambitious than it sounds

• Going from about US$196 bn (2026) to US$300 bn (2030) needs growth of roughly 11% a year [1].
• The past four years saw a 17.9% CAGR (Compound Annual Growth Rate, the average yearly growth) [3].

• So, on past trend, the target is within reach. The real test is whether the growth comes from new biomanufacturing or simply from more of existing products, such as ethanol and generic medicines [3].

• A rising dollar figure is not the same as more innovation

• The bioeconomy figure counts the size of a whole sector. It does not count new technologies created in India.
• The minister's own aim is "indigenous solutions with global relevance" [1]. Patents filed, licences sold and products exported would track that aim better than sector size alone.

11. Who Must Act for the Appeal to Become Results

• ANRF and DST should publish where the RDI money goes
• The scheme gives ANRF the money and makes DST responsible for running it [8].

• Regular public figures on loans approved, money actually paid out and sectors funded would show whether private R&D spending is really rising above its 36% share [6].

• NQM should report each target on its own

• Satellite links, inter-city QKD, qubit count and sensors (atomic clocks, magnetometers) are separate deliverables with separate deadlines [2].

• Reporting each one separately would stop one fast-moving strand from hiding slow progress in another.

• Companies have to spend their own money, as Korea and Israel did

• In those countries, research is paid for mostly by firms, not the state [9].
• Chambers like PHDCCI can bring researchers and businesses together [1]. But the share of GERD paid by companies is the number that will show whether the 2047 aim is being met [6].

12. Anchors for Answers

• Data: GERD is 0.64% of GDP (Economic Survey 2025-26). The government pays about 64% and the private sector about 36% [6].
• Data: Business pays for 73% of all R&D in OECD countries (2024). Israel spends 6.8% of its GDP on R&D and Korea 5.1% [9].
• Data: India is 3rd in pharma by volume but 14th by value, which shows the gap between making medicines and inventing them [3].
• Comparison: In China, South Korea and the US, the private sector pays for more than 70% of R&D, against about 36% in India [7][6].
• Scheme: RDI Scheme, ₹1 lakh crore over six years. It gives low or nil-interest long-term loans through a Special Purpose Fund in ANRF, focused on higher-TRL projects in sunrise sectors, and sets up a Deep-Tech Fund of Funds [8].
• Scheme: National Quantum Mission, ₹6003.65 crore (2023-24 to 2030-31). Its targets cover communication, computing and sensing [2].

13. Mains Relevance

• GS-III: Science & Technology (developments and their applications; indigenisation of technology and developing new technology); Indian economy (growth, investment); Internal security (security dimension of communication networks).
• GS-II (minor): Government policies and interventions for development.
• Possible question stems: 1. "India must move from technology adoption to technology creation." Discuss the role of industry–academia linkages in achieving technological sovereignty by 2047. 2. Examine the strategic significance of quantum-secure communication for India. How far has the National Quantum Mission advanced its goals? 3. The bioeconomy is emerging as a growth engine for India. Evaluate the BioE3 Policy's potential to deliver on economy, environment and employment.

14. Related Topics to Study Next

• Anusandhan National Research Foundation (ANRF): the institutional channel for private R&D funding linked to the RDI initiative.
• RDI Scheme: the main financing instrument for private R&D in sunrise and strategic sectors.
• Space sector reforms (IN-SPACe, private launches): the minister's own example of policy-led private participation [1].
• Quantum Key Distribution (QKD) and post-quantum cryptography: the technical basis of "quantum-secure" communication.
• National Biopharma Mission and BIRAC: earlier biotech commercialisation architecture [3].
• Ethanol Blending Programme: the bioenergy pillar of the bioeconomy [3].
• IndiaAI Mission and semiconductor mission: other frontier technologies where the minister tied self-reliance to indigenous capability and energy security [1].
• Viksit Bharat @2047: the overarching national goal the speech refers to [1].

15. NCERT Concepts to Revise

• Bioeconomy (Economy): The note's central data point: bioeconomy growth from US$10 bn to about US$196 bn and the BioE3 policy.
• Self-reliance (Economy): The minister's call to create indigenous technology instead of adopting foreign technology is a self-reliance argument.
• Sovereignty (Polity): He links domestic capability in strategic technologies to 'strategic sovereignty', so you need to know what sovereignty means.
• Private sector (Economy): The core problem is that private firms fund only about 36% of R&D, and the RDI scheme tries to raise this.
• Deep-tech startup (Economy): Quantum and biotech ventures need long, heavy R&D, which is why the RDI scheme backs them with a Deep-Tech Fund of Funds.
• Fund of funds (Economy): The RDI scheme sets up a Deep-Tech Fund of Funds that invests in venture funds, which then back start-ups.

16. Common Errors / Trap Areas

• NQM numbers: the target is 2,000 km over 8 years; 1,000 km is the milestone reached in 3 years. Don't swap them. The outlay is ₹6003.65 crore, often rounded to ₹6,000 crore [1][2].
• Bioeconomy figures differ by year: US$165.7 bn is the 2024 figure [3]; about US$196 bn is the minister's 2026 figure; the release headline says "exceeds US$195 bn" [1]. Check which year a question refers to.
• The minister's status: Dr. Jitendra Singh is MoS (Independent Charge) for S&T and Earth Sciences, but only MoS (not Independent Charge) in the PMO, DAE and Department of Space [1].
• BioE3 expansion: the third "E" is Employment, not Energy [3].
• Mission ownership: NQM sits under the Department of Science & Technology; National Biopharma Mission is DBT/BIRAC [2][3].